U.S. markets closed

  • S&P 500

    3,756.07
    +24.03 (+0.64%)
     

  • Dow 30

    30,606.48
    +196.92 (+0.65%)
     

  • Nasdaq

    12,888.30
    +18.28 (+0.14%)
     

  • Russell 2000

    1,974.86
    -5.14 (-0.26%)
     

  • Crude Oil

    48.42
    -0.10 (-0.21%)
     

  • Gold

    1,901.60
    +6.50 (+0.34%)
     

  • Silver

    26.52
    +0.11 (+0.43%)
     

  • EUR/USD

    1.2231
    0.0000 (-0.00%)
     

  • 10-Yr Bond

    0.9170
    -0.0090 (-0.97%)
     

  • GBP/USD

    1.3665
    0.0000 (-0.00%)
     

  • USD/JPY

    103.1910
    0.0000 (0.00%)
     

  • BTC-USD

    29,330.73
    -60.84 (-0.21%)
     

  • CMC Crypto 200

    541.66
    +7.38 (+1.38%)
     

  • FTSE 100

    6,460.52
    -95.30 (-1.45%)
     

  • Nikkei 225

    27,444.17
    -123.98 (-0.45%)
     

5 Value Stocks In The Energy Sector

Benzinga Insights
·2 min read

Understanding Value Stocks

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga Insights has compiled a list of value stocks in the energy sector that may be worth watching:

  1. Dynagas LNG Partners (NYSE:DLNG) - P/E: 4.98

  2. Smart Sand (NASDAQ:SND) - P/E: 1.63

  3. Navios Maritime (NYSE:NNA) - P/E: 1.1

  4. Euronav (NYSE:EURN) - P/E: 2.48

  5. Noble Midstream Partners (NASDAQ:NBLX) - P/E: 5.06

Dynagas LNG Partners has reported Q3 earnings per share at 0.21, which has increased by 5.0% compared to Q2, which was 0.2. Its most recent dividend yield is at 11.0%, which has increased by 4.95% from 6.05% in the previous quarter.

Smart Sand's earnings per share for Q3 sits at -0.09, whereas in Q2, they were at 0.12. Smart Sand does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.

Navios Maritime has reported Q3 earnings per share at -0.23, which has decreased by 111.44% compared to Q2, which was 2.01. The company's most recent dividend yield sits at 4.36%, which has decreased by 22.07% from 26.43% last quarter.

Euronav has reported Q3 earnings per share at 0.22, which has decreased by 81.82% compared to Q2, which was 1.21. Its most recent dividend yield is at 4.86%, which has decreased by 14.17% from 19.03% in the previous quarter.

Noble Midstream Partners's earnings per share for Q3 sits at 0.4, whereas in Q2, they were at 0.53. Most recently, the company reported a dividend yield of 8.77%, which has decreased by 0.11% from last quarter's yield of 8.88%.

These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Latest Stories

  • Dow Jones Gains As Schumer Offers McConnell Stimulus Bargain; Tesla Surges, Apple Falls Again

    The Dow Jones slipped as Senate Minority Leader Chuck Schumer attempted to strike a Covid-19 stimulus check bargain with Republican rival Mitch McConnell.

  • The second U.S. stimulus payments could arrive soon. Here's what to consider before you spend it.

    Some consumers may be shocked to receive Visa debit cards with stimulus cash in January. Don't throw the cards out, plus more Stimulus 2.0 tips.

  • 12 Stocks Turned $10,000 Into $1.7 Million In 12 Months

    It's been quite a year of contrasts for investors. Own the wrong S&P 500 stocks and you lose billions, but huge gains were there for the taking, too.

  • Dow Jones Futures: Stock Market Rally Lessons For 2021; Tesla, Nio Await Key News; 25 Stocks In Buy Range Now

    After the surprising 2020 stock market rally, here are key lessons for 2021. Tesla and Nio sales loom. Check out 25 stocks in buy zones.

  • Bill Ackman Crushed The Market Again In 2020

    Rumors of Bill Ackman's demise were greatly exaggerated. After a brutal three-year stretch from 2015 to 2017, Ackman's Pershing Square Holdings Ltd (OTC: PSHZF) has now put together back-to-back years of stellar returns, and Ackman has eased fears that he lost his stock-picking touch.As of Dec. 22, Pershing Square's net asset value was up 67.5% year-to-date in 2020. Pershing Square's stock is also up 82% in 2020, crushing the S&P 500's 15.4% gains. From 2015 to 2017, Ackman's fund lost about 30% of its NAV and lagged the S&P 500 by about 60%. However, Ackman followed up his 58% NAV gain in 2019 with another big year in 2020.Related Link: Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their PortfoliosAckman's Huge Year: Ackman boosted his 2020 returns with a spectacular $27-million short bet on corporate bonds back in March that ultimately netted him a $2.6-billion profit in what some have called one of the greatest trades in history.Ackman also made headlines this year by raising $4 billion to launch his Pershing Square Tontine Holdings Ltd (NYSE: PSTH) SPAC, which is now the largest SPAC in the market.At the time of the IPO in July, Ackman said the SPAC planned to take about six months to identify a target and announce a deal in the first quarter of 2021.Even after Pershing Square's big run in 2020, the stock still trades at a significant discount to NAV. Pershing's stock investing portfolio is relatively concentrated. As of the firm's most recent quarterly filing, Pershing held shares of just seven stocks.His three largest holdings include Lowe's Companies Inc (NYSE: LOW), Chipotle Mexican Grill, Inc. (NYSE: CMG) and Restaurant Brands International Inc (NYSE: QSR).Benzinga's Take: Ackman has a long track record of home run trades and dud investments. In years like 2020, he seems like an investing genius, while past losing bets on Valeant Pharmaceuticals and Borders bookstores have left investors scratching their heads.Investors should look for Ackman and his fund to continue to be high-risk, high-reward investments in 2021 and beyond.See more from Benzinga * Click here for options trades from Benzinga * The S&P 500 Just Did Something That Has Been Bullish Every Time Since WWII * 10 Best Performing S&P 500 Stocks Of 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • 6 Social Security Changes for 2021

    Every October, the Social Security Administration (SSA) announces its annual changes to the Social Security program for the coming year. Here are the Social Security changes that were announced in Oct. 2020 to take effect on Jan. 1, 2021, according to the SSA's annual fact sheet. Keep them in mind when you update your Social Security information. For 2021, nearly 70 million Social Security recipients are seeing a 1.3% cost-of-living adjustment (COLA) to their monthly benefits. The adjustment helps benefits keep pace with inflation and is based on the Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W) as calculated by the Bureau of Labor Statistics (BLS).

  • 3 Big Dividend Stocks Yielding Over 7%; Raymond James Says ‘Buy’

    Wall Street’s investment firms are burning the midnight oil as we approach the end of 2020, publishing their year-end notes and their New Year prognostications, both for investors’ edification. There is the obvious point: we’re in a moment of rising markets, and investor sentiment is riding high now that the election is settled and COVID vaccines have emergency approval and are getting into the distribution networks.However, the lockdown policies put in place to combat the virus this winter are slowing down the economic recovery. Whether the economy will truly tank or not is yet to be seen.In the meantime, Raymond James strategist Tavis McCourt has published his take on the current situation, and his comments bear consideration. First, McCourt notes the investors are focused on the good news: “[The] equity market is more focused on vaccine deployment and complete re-openings of economies in 2021, and so far, negative data points have been largely brushed aside.”Looking ahead, McCourt writes of the next two years: “We believe the logical outcome of 2021 (and 2022 for that matter) is a likely "return to normalcy" with strong EPS growth offset by lower P/Es barring a change in the vaccine story. We expect cyclical sectors and smaller cap equities to continue to outperform, as is typical in early cycle markets…”The research analysts at Raymond James have been searching the markets for the ‘right’ buys, and their picks bear a closer look. They’ve been tapping high-yielding dividend payers as an investment play of choice.The TipRanks database sheds some additional light on three of JMP’s picks – stocks with dividends yielding 7% or better – and that the investment firm sees with 10% upside or better.New Residential Investment (NRZ)The real estate investment trust (REIT) segment has long been known for its high and reliable dividends, a feature promoted by tax regulations which stipulate that these companies must return a certain proportion of profits directly to investors. Based in New York City, New Residential Investment is typical of its sector. The company’s portfolio includes residential mortgages, mortgage loan servicing rights, and loan origination. NRZ focuses its operations on the residential housing sector.NRZ is a mid-cap company, with a market value of $4.13 billion and a portfolio worth $5.72 billion. The company’s revenues have been rising since the second quarter of 2020, after steep losses during the ‘corona recession’ of Q1. The third quarter earnings, however, came in at 19 cents per share, down from 54 cents in the year-ago quarter. But even with that loss, NRZ took care to maintain the dividend.In fact, it did more than that. The company raised the Q3 dividend, to 15 cents per common share, in a continuation of an interesting story. Back in Q1, the company pared back the common share dividend to 5 cents, in a move to preserve capital during the corona crisis. The company has since raised the dividend by 5 cents in each subsequent quarter, and the Q4 payment, announced in mid-December, is for 20 cents per common share. At that rate, the dividend annualizes to 80 cents and the yield exceeds 7.87%.In addition to raising the dividend, NRZ has also announced a share buyback program totaling $100 million. The repurchase is for preferred stock shares, and goes alongside the existing repurchase policy of common shares.Analyst Stephen Laws, in his coverage of NRZ for Raymond James, writes, “We expect strong origination volumes and attractive gain on sale margins to drive strong near-term results, and we continue to expect a dividend increase in 4Q [...] For 4Q20, we are increasing our core earnings estimate by $0.02 per share to $0.35 per share. For 2021, we are increasing our core earnings estimate by $0.08 per share to $1.31 per share."In line with these comments, Laws rates the stock an Outperform (i.e. Buy). His $11.50 target price implies a one-year upside of 16%. (To watch Laws’ track record, click here)It’s not often that the analysts all agree on a stock, so when it does happen, take note. NRZ’s Strong Buy consensus rating is based on a unanimous 8 Buys. The stock’s $11.36 average price target suggests a 14% and a change from the current share price of $9.93. (See NRZ stock analysis on TipRanks)Fidus Investment Corporation (FDUS)Next up is a business development corporation, Fidus Investment. This company is one of many in the mid-market business financing niche, offering debt solutions and capital access to smaller firms that may not be able to secure lending from the larger markets. Fidus’ portfolio focuses on senior secured debt and mezzanine debt for companies valued between $10 million and $150 million.Fidus has investments in 68 companies with an aggregate value of $697 million. The largest portion of that portfolio, 59%, is second-lien debt, with the rest divided mainly between subordinated debt, first-lien debt, and equity-related securities.The company has seen revenues gain through the second and third quarters of 2020, after negative results in Q1. The third quarter top line came in at ~$21 million, up an impressive 129% sequentially. Since the third quarter, Fidus has declared its dividend for Q4, at 30 cents per common share, the same as the previous two quarter, plus an extra 4-cent special dividend authorized by the Board of Directors. This brings the total payment for the quarter to 34 cents per common share, and puts the yield at 9.5%.Raymond James analyst Robert Dodd likes what he sees in Fidus, especially the dividend prospects. “We continue to see the risk / reward as attractive at current levels - with shares trading below book, solid forecasted base dividend coverage from NII… We project FDUS solidly over-earning its quarterly base dividend of $0.30 / share through our projection period. As a result, we do project modest supplementals…”Dodd puts an Outperform (i.e. Buy) rating on the stock, and sets a target price of $14. At current levels, that target indicates an upside of 10.5% in the next months. (To watch Dodd’s track record, click here)Wall Street is somewhat more divided on FDUS shares, a circumstance reflected in the Moderate Buy analyst consensus rating. That rating is based on 4 reviews, including 2 Buys and 2 Holds. Shares are priced at $12.66, and the $13.33 average price target suggests a modest 5% upside from current levels. (See FDUS stock analysis on TipRanks)TPG RE Finance Trust (TRTX)Returning to the REIT sector, we look at TPG RE Finance Trust, the real estate financing arm of global asset firm TPG. This REIT, with an $820 million market cap, has built a portfolio of commercial mortgage loans worth an aggregate total of $5.5 billion. The company is a provider for original commercial mortgage loans starting at $50 million, mainly in US primary markets. The largest share of the company’s loans and properties are centered in the East.Like many finance companies, TPG RE Finance saw serious losses in Q1 due to the corona pandemic crisis – but has since recovered to a large extent. Revenues in Q3 hit $48 million, up 9% year-over-year. During the quarter, TPG received loan repayments totaling $199.6 million, a solid result, and when the quarter ended the company had on hand $225.6 million in cash or cash equivalents.The company was able to easily fund its dividend, of 20 cents per common share, in Q3. For Q4, the company has recently declared not just the 20-cent regular payment, but also an 18-cent non-recurring special cash dividend. Taken together, the dividends give a yield of 7.5%, almost 4x higher than the average found among S&P-listed companies.Returning to Raymond James’ REIT expert Stephen Laws, we find that he is bullish on TRTX, too. “TRTX has underperformed since reporting 3Q results, which we believe creates an attractive buying opportunity… We expect core earnings to continue benefiting from LIBOR floors in loans and expect new investments to resume in 1Q21. The company's portfolio has combined retail and hotel exposure of 14%, which is below the sector average of 19%...” To this end, Laws rates TRTX a Strong Buy and his $13 price target suggests ~22% upside in 2021. (To watch Laws’ track record, click here)This stock also holds a Strong Buy rating from the analyst consensus, based on 3 unanimous Buy reviews set in recent weeks. Shares are priced at $10.67 and the average target of $11.00 suggests a modest 3% upside from current levels. (See TRTX stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • How to Set Up a Backdoor Roth IRA

    Discover how a backdoor Roth IRA works, how to set one up, the rules to follow, and when a backdoor IRA might not be right for you.

  • These are the 7 biggest tax changes for 2021

    Here's what'll be new when you sit down to do your 2020 taxes in the new year.

  • Congress (finally) passed new stimulus checks — here's when to expect yours

    Plus, how much will you get?

  • Barron’s Best Income Investments for 2021

    The bond market has been a barren field for income, as fixed-income yields remain stuck at historic lows. “With rates just barely above all-time lows, yield opportunities are clustered in the equity markets,” says David King, co-manager of the Columbia Flexible Capital Income fund. King says that income-hungry investors need look no further than the so-called Dogs of the Dow, the 10 highest-yielding stocks in the 30-stock Dow Jones Industrial Average.

  • Bristol-Myers Derivative Is Now Worthless as Key Deadline Passes

    (Bloomberg) -- Investors in a deal sweetener created when Bristol-Myers Squibb Co. acquired Celgene Corp. in 2019 have seen their all-or-nothing bet wiped out because U.S. regulators didn’t approve a drug in time.The contingent value right, or CVR, depended on a trio of drug candidates getting cleared. In a statement early Friday, Bristol-Myers said the second key deadline -- approval for lymphoma cell therapy liso-cel -- expired on Dec. 31 without a decision from the Food and Drug Administration. The CVR’s final hurdle would have been approval by March 31 for another new therapy called ide-cel.The $9-a-share sweetener traded as high as $4.76 apiece in April before falling to 49 cents in extended trading Thursday. There are almost 715 million CVRs outstanding, which would have translated to a total payout of $6.4 billion if all the terms were met, data compiled by Bloomberg show. The CVRs will no longer trade on the New York Stock Exchange.Bristol-Myers said it continues to work closely with the FDA to support the review of the Biologics License Application for liso-cel and still wants to bring the therapy to patients.In a note Dec. 23, Mizuho analyst Salim Syed highlighted how rare it is for the FDA to approve drugs between the Christmas and New Year’s Day holidays. He estimated the CVR’s litigation value at 30 cents to $1.40.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Here’s why the Georgia runoff elections for the U.S. Senate could turn into a ‘big deal’ for markets

    The looming Georgia runoff elections next Tuesday could inject volatility in a high-flying stock market that has mostly looked past politics in favor of the brighter economic outlook next year.

  • Semiconductor Stocks To Buy And Watch Ahead Of Q4 Earnings Season

    Finding top semiconductor stocks to buy involves understanding the health of markets that purchase chips for their products. Chip stocks rose in 2020 as the industry emerged from a downturn.

  • 6 ETFs that Could Be Recession-Proof

    If you’re worried about the stock market correcting, or eventually heading into bear market territory, then you will want to consider the exchange-traded funds (ETF) covered below. They will all give you more downside protection than the vast majority of ETFs throughout the ETF universe.

  • We Found a Bubble–but It May Not Be What You Think It Is

    At least there was the stock market. Despite the Covid-19 pandemic, which ground the U.S. economy to a halt, the Dow and the rest of the major indexes finished the year at or near record highs. As is so often the case when there is a wide chasm between stock market gains and economic pain, many investors start to wonder if we’ve witnessed a massive financial bubble.

  • 3 “Strong Buy” Stocks From the Best Analysts on Wall Street

    At long last, the annus horribilus 2020 is coming to an end, and it’s time to get our portfolios in order for the new year ahead. There is good news about to encourage investors for 2021. In proof that government sometimes can move with speed and decision, FDA granted emergency authorization for both the Pfizer and Moderna COVID vaccines, and the shots are getting into the distribution networks. The election is settled, except for the Georgia Senate runoffs, but no matter how those turn out the overall results is known: a closely divided government, without a clear mandate for sweeping legislation. It’s a portent of regulatory stasis, which means predictability, which is good for markets.These are the facts behind the rising investors sentiment, which has pushed the Dow Jones, the S&P 500, and the NASDAQ all up to record levels. And its’ that upbeat sentiment which has Wall Street’s top analysts selecting stocks as potential winners for the year ahead.And when we say it’s Wall Street’s top analysts making these calls, we mean it. These are stock picks from analysts among the top 5 in the TipRanks database. These are the stock experts with the most recommendations on file, the best success rate, and the highest average return. So, let’s see what they have to say about these three Strong Buy stocks.ZoomInfo Technologies (ZI)Tech companies, especially in the cloud, communications, and marketing segments, have some clear opportunities during the COVID pandemic. ZoomInfo is part of this group; the company’s services include digital marketing intelligence, account and data management, demand generation, and lead prospecting. ZoomInfo offers AI cloud software designed to makes these background tasks more efficient, so that sellers can focus on selling.ZI shares have seen volatile trading since going public in June of 2020, but overall, the stock is up 34% year-to-date.The third quarter, ZoomInfo’s first full quarter as a public company, showed strong results to encourage investors. Top line revenue hit $123.4 million, up 11.8% sequentially and 56% year-over-year. EPS, which had been negative in Q2, turned positive in Q3 with a 2-cent per share profit. The company finished the quarter with $59.8 million in free cash flow. ZoomInfo reported having 720 customers with $100,000 or more in annual contract value.In his review of ZoomInfo, Piper Sandler's Brent Bracelin, rated the 1 analyst on Wall Street by TipRanks, lays out a straightforward bullish case.“We are raising revenue estimates by $13.6M for this year and $19.6M for next year factoring in broad-based strength and minor contributions from Everstring and Clickagy acquisitions. We are buyers of ZI based on its ambitions to build a modern go-to-market (GTM) operating system with a unique business model balancing high-growth and high margins… Based on strong Q3 results and favorable Q4 outlook, we would be aggressive buyers of ZI given its unique profile of a high-growth and high-margin model with limited downside risk,” Bracelin opined.Bracelin sets a $59 price target to go along with this Overweight (i.e. Buy) rating, suggesting that ZI has room for ~25% growth next year. (To watch Bracelin’s track record, click here)Overall, there are 9 recent reviews on record for ZoomInfo and all are Buys – making the analyst consensus rating a unanimous Strong Buy. Shares are priced at $47.03 and the average price target of $55.89 indicates ~19% upside potential from that level. (See ZI stock analysis on TipRanks)Ichor Holdings (ICHR)Next up is a holding company, whose subsidiaries design, engineer, and manufacture gas and chemical fluid delivery systems essential in a variety of industries. Ichor is best known for its contributions to the semiconductor industry’s capital equipment, where its gas module and chemical process subsystems make up a substantial portion of each chip’s cost. Ichor’s systems are also used in the manufacture of LED displays, biomedical equipment, and alternative energy sources.Specialized manufacturing can be a solidly profitable niche, especially when a company is building parts and tools necessary to top-line industries. Semiconductor chips are essential in the digital world, and they cannot be manufactured without input from Ichor’s tools. This gives Ichor a competitive advantage, as it offers a product that its customers cannot do without.This can be seen in the quarterly revenues, which have been rising slowly but steadily through 2020. The company saw $220 million at the top in Q1, and reported $228 million in Q3. The third quarter was up 47% year-over-year, and was the sixth quarter in a row to show sequential gains. EPS, at 45 cents per share, was up 28% yoy.Among the fans is Needham's Quinn Bolton, who's ranked 2 on Wall Street, according to TipRanks.“[We] believe Ichor's fundamentals remain strong… we expect the offering will enable ICHR to pursue meaningful accretive M&A that should strengthen its market position, accelerate revenue growth and provide for vertical integration and higher gross margin over time. Looking further out, should the company achieve its LT operating model over the next ~3 years, we see NG earnings power of $4.85 per share,” Bolton commented. To this end, Bolton rates the stock a Buy, and his $40 price target implies a one-year upside of 32%. (To watch Bolton’s track record, click here)Like Bolton, Wall Street is picking ICHR as a long-term winner. With 4 unanimous Buy ratings assigned over the last three months, the stock earns a Strong Buy analyst consensus. Adding to the good news, its $40 average price target puts the upside potential at ~32%. (See ICHR stock analysis on TipRanks)DocuSign (DOCU)Last but not least is DocuSign, the cloud-based electronic signature service from San Francisco. DocuSign offers customers a verified and secure electronic signature option for online documents. Customers reap savings from efficiency, in the form of faster turnaround, less ink and paper used in printing, and less time spent printing and distributing hard copies for signature.DocuSign shares have seen a steep appreciation in 2020, as the move toward remote work and virtual offices put a premium on digital services and online verification. DOCU is up 205%, more than tripling its value this year. The stock has gained as the company’s revenues have gone up. The top line rose 29% between Q1 and Q3, with the third quarter number hitting $382.9 million. Earnings in the third quarter were up an impressive 53% year-over-year. The yoy increase in free cash flow was even more impressive, turning from negative $14 million to a surplus of $38 million.All of this leads RBC's Alex Zukin, the 3 analyst in the TipRanks database, to rate DOCU an Outperform (i.e. Buy) along with a $325 price target. Investors stand to pocket a 44% gain should the analyst's thesis play out. (To watch Zukin’s track record click here)Backing his stance, Zukin writes, “[The] Beats go on as DOCU delivered another very strong quarter of acceleration on every metric... What is even more impressive in our minds is that this is being driven almost entirely by an acceleration of the core e-signature business with the company being confident that it is still very modestly penetrated in its TAM (which has expanded significantly) that they can maintain growth above pre-pandemic levels in a post-pandemic world…” Similarly, other Wall Street analysts like what they’re seeing. With 10 Buy ratings vs 3 Holds received in the last three months, the stock earns a Strong Buy consensus rating. At a $276.46 average price target, analysts see ~22% upside potential in store for DocuSign. (See DOCU stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • NYSE to delist 3 biggest Chinese telecoms to comply with Trump executive order

    The New York Stock Exchange announced late Thursday it has begun delisting proceedings three Chinese telecommunications companies in order to comply with an executive order by President Donald Trump targeting companies affiliated with China's military.

  • Merck Is One of Barron’s Top Stock Picks for the New Year. Here’s Why.

    Merck was slow in developing a Covid-19 vaccine but it has one of the industry’s best overall vaccine franchises, led by Gardasil for cervical cancer.

  • After golden year for precious metals, silver set to shine in 2021

    After a spectacular year, precious metals are set for further gains in 2021, with silver tipped to outperform, but analysts are growing more cautious about the prospects for gold as the global economy recovers from the impact of the coronavirus. This, alongside supply deficits, pushed gold and palladium prices up by more than 20% this year, while silver rose 47%, and platinum 10%. "We are going to see new record highs for gold and palladium (in 2021)," said Philip Newman at consultants Metals Focus.